$614 EpiPen only had $30 production cost

But industry insiders have shared that the production price per device, which is sold in the market for $614, is no more than $30.

Kevin Deane, head of medical technologies for PA Consulting Group, has told NBC News that expenses for the EpiPen's base components, which included a needle, a tube and a plastic cap, cost about $2-$4 to buy.

The epinephrine medication is worth around a dollar.

However, considering that Mylan will be paying for the research and development processes of the auto-injector, which in this case is Pfizer's Meridian Medical Technologies, the amount can generally multiply two to five times.

Mylan Company instigated an outrage last month when an estimated 400 percent in price hike for its EpiPen item was unveiled.

The situation has been further aggravated by a report that the salary of CEO Heather Breash jumped to almost $20 million or a valuation of 600 percent in 2015.

The embattled chief has shifted the blame to the wholesalers, the distributors and other go-betweens between the company and the consumers. However, under standard industry practices, most middlemen only get a single digit percentage aside from the insurer's portion.

Adam Fein, president of Pembroke Consulting, a healthcare firm that advises drug manufacturers on commercial issues, shares that Mylan has a couple of factors that triggered the issue.

First, the company has monopolized a part of the market that is associated with the auto-injector. Second, the government has failed to institute control that would have provided competition in order to keep Mylan's reach market reach in check.

New York Attorney-General Eric Schneiderman has launched an investigation shortly after the group's price hike revelation. During a preliminary review of Mylan's sales contract with a local school system, potentially anti-competitive terms may have been found.

The company, however, responded that no purchase requirements are needed for the program nor have there ever been free EpiPen distribution.

Meanwhile, a new class action lawsuit has been brought up against Mylan with regards to the two-pack sale of the auto-injector device.

The charge has been considered as a pretense for charging unconscionable prices and misstating the dosage in order to purportedly justify price gouging which is in violation with the unfair trade practice and consumer protection laws.

In response, the company's move is conformity of a then new government guideline, which recommended doctors to prescribe two doses of epinephrine for those who have experienced life-threatening allergic reaction anaphylaxis.